Profil bibliographique

Katrina Kao

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

70Publications signalées

479Citations signalées

0Affiliations récentes

Les domaines associés

Colorectal Cancer Treatments and StudiesCancer Genomics and DiagnosticsGenetic factors in colorectal cancerLipid metabolism and disordersCancer Immunotherapy and Biomarkers

Les publications récentes

Accès ouvert 2026 other OpenAlex

Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.

0 citations

Accès ouvert 2026 other OpenAlex

Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Table S3

0 citations

Accès ouvert 2026 other OpenAlex

Table S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Table S1

0 citations

Accès ouvert 2026 other OpenAlex

Figure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).

0 citations

Accès ouvert 2026 other OpenAlex

Table S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Table S4

0 citations

Accès ouvert 2026 other OpenAlex

Figure S4 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Supplementary Figure S4: Tumor immune microenvironment in a colorectal cancer patient with acquired resistance to pembrolizumab and trebananib.

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.

0 citations

Accès ouvert 2026 other OpenAlex

Table S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Table S2

0 citations

Accès ouvert 2026 other OpenAlex

Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Brandon M. Huffman, Osama E. Rahma, Kevin Tyan, Yvonne Li et autres

Supplementary Figure S5: Survival by ERBB2 status.

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S3 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen et autres

Receiver operating curve demonstrating relationship between tumor mutational burden and clinical benefit

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table S3 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen et autres

Antigen retrieval, primary antibody incubation, and OpalTM Fluorophore incubation for multiplex immunofluorescence

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure S4 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen et autres

Mutations across genes by type and/or frequency

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.